Effectts of three low-dose oral contraceptive formulations on lipid metabolism

S. Bertolini, N. Elicio, R. Cordera, G. L. Gapitanio, G. Montagna, S. Croce, M. Saturnino, R. Balestreri, L. De Cecco

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Three oral contraceptive preparations were studied in 60 healthy women. This randomized, comparative, baseline controlled study was designed to investigate the effects of the preparations on plasma lipids and lipoproteins. The following formulations were studied: a monophasic preparation containing ethinylestradiol and desogestrel (M-DSG) and two triphasic formulations containing ethinylestradiol and gestodene or levonorgestrel respectively (T-GSD and T-LNG). These preparations were studied for six treatment cycles. Total cholesterol and apoprotein B did not change in any group. Low density lipoprotein (LDL) cholesterol was significantly decreased in the groups of women treated with M-DSG and T-GSD respectively. No changes were observed in the T-LNG group. With M-DSG, significant increases were observed in high-density lipoprotein (HDL) cholesterol and HDL3 cholesterol, whilst HDL2 cholesterol did not change. With both T-GSD and T-LNG, no changes were observed in HDL cholesterol, whilst a significant increase in HDL3 cholesterol together with a trend to decrease in HDL2 cholesterol were observed. Apolipoprotein AI increased with the following ranking M-DSG>T-GSD>T-LNG. The LDL/HDL cholesterol ratio significantly decreased with both M-DSG and T-GSD. In the T-LNG group there was no change in this ratio. Triglycerides increased to the same extent in all treatment groups. As far as concerns the risk of arterial diseases, these three oral contraceptive formulations mostly induced negligible and/or partly favorable changes in plasma lipids and lipoproteins; however, the lipoprotein pattern during M-DSG treatment resulted better than during T-GSD, and the latter turned out to be better than during T-LNG.

Original languageEnglish
Pages (from-to)327-332
Number of pages6
JournalActa Obstetricia et Gynecologica Scandinavica
Volume66
Issue number4
Publication statusPublished - 1987

Fingerprint

Oral Contraceptives
Lipid Metabolism
HDL Cholesterol
Lipoproteins
Ethinyl Estradiol
Desogestrel
HDL3 Lipoprotein
Lipids
Levonorgestrel
Apolipoprotein A-I
Apolipoproteins B
LDL Lipoproteins
LDL Cholesterol
Triglycerides
Therapeutics
Cholesterol

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Bertolini, S., Elicio, N., Cordera, R., Gapitanio, G. L., Montagna, G., Croce, S., ... De Cecco, L. (1987). Effectts of three low-dose oral contraceptive formulations on lipid metabolism. Acta Obstetricia et Gynecologica Scandinavica, 66(4), 327-332.

Effectts of three low-dose oral contraceptive formulations on lipid metabolism. / Bertolini, S.; Elicio, N.; Cordera, R.; Gapitanio, G. L.; Montagna, G.; Croce, S.; Saturnino, M.; Balestreri, R.; De Cecco, L.

In: Acta Obstetricia et Gynecologica Scandinavica, Vol. 66, No. 4, 1987, p. 327-332.

Research output: Contribution to journalArticle

Bertolini, S, Elicio, N, Cordera, R, Gapitanio, GL, Montagna, G, Croce, S, Saturnino, M, Balestreri, R & De Cecco, L 1987, 'Effectts of three low-dose oral contraceptive formulations on lipid metabolism', Acta Obstetricia et Gynecologica Scandinavica, vol. 66, no. 4, pp. 327-332.
Bertolini S, Elicio N, Cordera R, Gapitanio GL, Montagna G, Croce S et al. Effectts of three low-dose oral contraceptive formulations on lipid metabolism. Acta Obstetricia et Gynecologica Scandinavica. 1987;66(4):327-332.
Bertolini, S. ; Elicio, N. ; Cordera, R. ; Gapitanio, G. L. ; Montagna, G. ; Croce, S. ; Saturnino, M. ; Balestreri, R. ; De Cecco, L. / Effectts of three low-dose oral contraceptive formulations on lipid metabolism. In: Acta Obstetricia et Gynecologica Scandinavica. 1987 ; Vol. 66, No. 4. pp. 327-332.
@article{884da385ca9f4ae3891de7e7817f358e,
title = "Effectts of three low-dose oral contraceptive formulations on lipid metabolism",
abstract = "Three oral contraceptive preparations were studied in 60 healthy women. This randomized, comparative, baseline controlled study was designed to investigate the effects of the preparations on plasma lipids and lipoproteins. The following formulations were studied: a monophasic preparation containing ethinylestradiol and desogestrel (M-DSG) and two triphasic formulations containing ethinylestradiol and gestodene or levonorgestrel respectively (T-GSD and T-LNG). These preparations were studied for six treatment cycles. Total cholesterol and apoprotein B did not change in any group. Low density lipoprotein (LDL) cholesterol was significantly decreased in the groups of women treated with M-DSG and T-GSD respectively. No changes were observed in the T-LNG group. With M-DSG, significant increases were observed in high-density lipoprotein (HDL) cholesterol and HDL3 cholesterol, whilst HDL2 cholesterol did not change. With both T-GSD and T-LNG, no changes were observed in HDL cholesterol, whilst a significant increase in HDL3 cholesterol together with a trend to decrease in HDL2 cholesterol were observed. Apolipoprotein AI increased with the following ranking M-DSG>T-GSD>T-LNG. The LDL/HDL cholesterol ratio significantly decreased with both M-DSG and T-GSD. In the T-LNG group there was no change in this ratio. Triglycerides increased to the same extent in all treatment groups. As far as concerns the risk of arterial diseases, these three oral contraceptive formulations mostly induced negligible and/or partly favorable changes in plasma lipids and lipoproteins; however, the lipoprotein pattern during M-DSG treatment resulted better than during T-GSD, and the latter turned out to be better than during T-LNG.",
author = "S. Bertolini and N. Elicio and R. Cordera and Gapitanio, {G. L.} and G. Montagna and S. Croce and M. Saturnino and R. Balestreri and {De Cecco}, L.",
year = "1987",
language = "English",
volume = "66",
pages = "327--332",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Effectts of three low-dose oral contraceptive formulations on lipid metabolism

AU - Bertolini, S.

AU - Elicio, N.

AU - Cordera, R.

AU - Gapitanio, G. L.

AU - Montagna, G.

AU - Croce, S.

AU - Saturnino, M.

AU - Balestreri, R.

AU - De Cecco, L.

PY - 1987

Y1 - 1987

N2 - Three oral contraceptive preparations were studied in 60 healthy women. This randomized, comparative, baseline controlled study was designed to investigate the effects of the preparations on plasma lipids and lipoproteins. The following formulations were studied: a monophasic preparation containing ethinylestradiol and desogestrel (M-DSG) and two triphasic formulations containing ethinylestradiol and gestodene or levonorgestrel respectively (T-GSD and T-LNG). These preparations were studied for six treatment cycles. Total cholesterol and apoprotein B did not change in any group. Low density lipoprotein (LDL) cholesterol was significantly decreased in the groups of women treated with M-DSG and T-GSD respectively. No changes were observed in the T-LNG group. With M-DSG, significant increases were observed in high-density lipoprotein (HDL) cholesterol and HDL3 cholesterol, whilst HDL2 cholesterol did not change. With both T-GSD and T-LNG, no changes were observed in HDL cholesterol, whilst a significant increase in HDL3 cholesterol together with a trend to decrease in HDL2 cholesterol were observed. Apolipoprotein AI increased with the following ranking M-DSG>T-GSD>T-LNG. The LDL/HDL cholesterol ratio significantly decreased with both M-DSG and T-GSD. In the T-LNG group there was no change in this ratio. Triglycerides increased to the same extent in all treatment groups. As far as concerns the risk of arterial diseases, these three oral contraceptive formulations mostly induced negligible and/or partly favorable changes in plasma lipids and lipoproteins; however, the lipoprotein pattern during M-DSG treatment resulted better than during T-GSD, and the latter turned out to be better than during T-LNG.

AB - Three oral contraceptive preparations were studied in 60 healthy women. This randomized, comparative, baseline controlled study was designed to investigate the effects of the preparations on plasma lipids and lipoproteins. The following formulations were studied: a monophasic preparation containing ethinylestradiol and desogestrel (M-DSG) and two triphasic formulations containing ethinylestradiol and gestodene or levonorgestrel respectively (T-GSD and T-LNG). These preparations were studied for six treatment cycles. Total cholesterol and apoprotein B did not change in any group. Low density lipoprotein (LDL) cholesterol was significantly decreased in the groups of women treated with M-DSG and T-GSD respectively. No changes were observed in the T-LNG group. With M-DSG, significant increases were observed in high-density lipoprotein (HDL) cholesterol and HDL3 cholesterol, whilst HDL2 cholesterol did not change. With both T-GSD and T-LNG, no changes were observed in HDL cholesterol, whilst a significant increase in HDL3 cholesterol together with a trend to decrease in HDL2 cholesterol were observed. Apolipoprotein AI increased with the following ranking M-DSG>T-GSD>T-LNG. The LDL/HDL cholesterol ratio significantly decreased with both M-DSG and T-GSD. In the T-LNG group there was no change in this ratio. Triglycerides increased to the same extent in all treatment groups. As far as concerns the risk of arterial diseases, these three oral contraceptive formulations mostly induced negligible and/or partly favorable changes in plasma lipids and lipoproteins; however, the lipoprotein pattern during M-DSG treatment resulted better than during T-GSD, and the latter turned out to be better than during T-LNG.

UR - http://www.scopus.com/inward/record.url?scp=0023526297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023526297&partnerID=8YFLogxK

M3 - Article

C2 - 2962417

AN - SCOPUS:0023526297

VL - 66

SP - 327

EP - 332

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 4

ER -